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ABSTRACT 
 Autosomal Recessive Juvenile Parkinson’s (AR-JP) is a debilitating disease 
caused by loss of functions in the parkin gene.  The parkin protein normally functions as 
an E3 ligase in the ubiquitination pathway, a cellular process that facilitates the 
degradation of misfolded proteins.  A loss of parkin function results in the accumulation 
and aggregation of these misfolded proteins, causing cell death of dopaminergic neurons 
in patients’ brains.   It has been recently shown that parkin is directly associated with 
Nrdp1, another ubiquitin E3 ligase.  Further evidence indicates that Nrdp1 promotes 
parkin degradation and modulates parkin’s activities on its substrates.  We hypothesize 
that the regulation of interactions between parkin and Nrdp1 may affect the pathogenesis 
of PD.  In this MQP, a yeast two hybrid approach was used to identify the domain(s) of 
Nrdp1 that binds parkin.  Our long term goal is to design peptides against parkin-binding 
domain(s) in Nrdp1 so that interactions between these two proteins may be intervened. 
These peptides would have potential therapeutic uses. 
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BACKGROUND 
 
Parkinson’s Disease, Introduction   
 Description and Prevalence in U.S. 
 Parkinson’s disease (PD) is a neurodegenerative disorder first described by Dr. 
James Parkinson in 1817 (Parkinson's Disease: Signs and Symptoms, 2005).   He 
characterized the disease as shaky palsy.  It wasn’t until 1960, with the help of new 
technologies that changes in the brains of Parkinson’s patients were observed 
(Parkinson's Disease: Signs and Symptoms, 2005).  PD affects ~500,000 people in the 
United States alone, and is the most common movement disorder with about 1% of the 
population affected over the age of 65, which increases to 4% by age 85 (Giasson and 
Lee, 2001).  PD is a progressive disorder that is characterized by slowed movement, loss 
of muscle control, and poor balance (Parkinson’s Disease, 2005).   
The cause of the disease is still not completely understood, but it is characterized 
by the loss of dopamine receptor-containing (dopaminergic) neurons in the substania 
nigra and the accumulation of Lewy bodies (Zhang et al. 2000).  The loss of dopamine 
receptors causes delayed reactions and shakiness.  This is brought on by the deterioration 
of dopaminergic neurons in the substantial nigra. Lewy bodies are the abnormal 
clustering of proteins that form dense filamentous inclusions in the cytoplasm of the 
neurons (Giasson and Lee, 2001).  Although the underlying cause of the PD is unknown, 
it has been determined through recent studies that both environmental and genetic factors 
contribute to the onset of the disease.  Rotenone, for example, is used as a pesticide and 
can cause inhibition of ATP production by disrupting mitochondrial complex 1 (Betarbet 
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et al. 2000), which may destroy dopaminergic neurons.  On the other hand, six genes 
have been recently identified to be directly involved in the pathogenesis of the disease. 
 
Current Treatments 
 Current treatment options for PD vary depending on the severity and stage of the 
disease.  Early onset of the disease can be treated with a change in diet, exercise, and a 
combination of drugs to treat tremors.  Moderate symptoms are treated with drugs aimed 
at supplementing the neurotransmitter dopamine to interact with the reduced number 
receptors in the patients.  For long term treatment, dopamine is supplemented, and drugs 
aimed at increasing the half-life of dopamine in the body are administered (Parkinson’s 
Disease, 2005). 
 
Autosomal Recessive Juvenile Parkinson’s   
 
 Description and Prevalence   
 
 Most of Parkinson’s disease cases are sporadic. Less than 10% of PD have family 
history.  There are two forms of familial PD, autosomal recessive and autosomal 
dominant. The form of Autosomal Recessive Juvenile Parkinson’s disease (AR-JP) has 
an onset before age 40, but often earlier than age 20.   AR-JP is a very rare form of 
Parkinson’s disease, but the symptoms for AR-JP are typically similar to those of 
Parkinson’s patients, although they have a better response to dopamine treatments.  
Patients with AR-JP develop neuronal loss as in PD, but do not accumulate Lewy bodies 
(Parkinson’s Disease, 2005).   
Mutations in the parkin gene (discussed below) have been identified to play 
crucial roles in the onset of AR-JP.  Both alleles of the parkin gene are mutated in these 
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AR-JP patients.  Mutant forms of the gene express truncated or inactive forms of the 
parkin protein that are responsible for about 50% of AR-JP patients with a family history 
(Krüger, 2004).  These mutations are mostly classified by deletion of portions of the gene 
during transcription (Giasson and Lee, 2001).  But missense or nonsense mutations have 
also been described (see below).    
 
Parkinson’s Disease, Pathology Mechanism  
 
 Parkin   (discovery, size, structure, location, function)  
 
 The gene parkin linked to AR-JP was first discovered in a Japanese patient 
(Kitada et al. 1998).  By using a positional cloning strategy with exon trapping 
technology and cDNA library screening, Kitada et al., were able to isolate the gene in 
which exons 3-7 were deleted.  Subsequently, they identified a deletion of exon 4 in the 
same gene to 3 unrelated families with AR-JP, directly linking mutations in this gene to 
the pathology of the disease (Kitada et al. 1998). 
The parkin gene is located on chromosome 6 (see Figure 1) and spans 1.5 
megabases, making it one of the largest genes in the human genome.  It has a total of 12 
exons that encode a 465 amino acid protein with a molecular mass of 52 kDa (Giasson 
and Lee, 2001).  The amino acid sequence of parkin has a 62% homology to ubiquitin at 
the N-terminus (see Figure 2).  The carboxy terminus of the protein contains two RING-
finger motifs and an in-between RING finger (IBR) domain (see Figure 3) (Giasson and 
Lee, 2001). 
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Figure 1:  The Chromosomal Location of the parkin Gene (Mata et al. 2004). 
 
 
 
 
 
 
 
Figure 2: Amino Acid Alignment of Parkin and Ubiquitin Proteins (Kitada et al. 1998). 
 
 
 
Figure 3: Representation of the Parkin protein (Giasson and Lee, 2001).  
Known parkin point mutations and domains are shown above. 
 
 
E3  (discovery, size, structure, location, function)  
 Proteins are degraded in the cell through a natural process called the Ubiquitin 
Proteasome Pathway (UPP).  This pathway is important in the regulation of basic cellular 
processes, such as removal of misfolded, misfiled, mutated, or old proteins.  Ubiquitin 
(Ub), a 76 amino acid protein, is the primary component in the UPP and is one of the 
most abundant proteins in the body.  It functions as a tag protein, labeling proteins 
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targeted for degradation.  Ub is covalently linked to the substrate by formation of an 
isopeptide bond between its C-terminus and the amino group of a lysine residue of the 
target proteins.  A polyubiquitin chain is then formed on the protein through the ligation 
of additional monomers of Ub in successive rounds of ubiquitination. These Ub 
molecules are added to specific lysine residues on the nearest Ub of the elongating 
ubiquitin chain. Substrate proteins linked to polyubiquitin chains are recognized for 
degradation by the proteasome machinery (see Figure 4) (Iechanover, 2001). 
 
 
 
 
 
 
 
 
  Figure 4:  The Ubiquitination Pathway for Protein Degradation (Goldberg, 2001). 
 
This protein degradation process involves a series of steps, where several 
enzymes are required to ensure specificity and to activate the Ub complex.  The first step 
involves the ubiquitin-activating enzyme (E1), which activates ubiquitin by forming a 
linkage between the two.  This activated ubiquitin is transferred to ubiquitin-conjugating 
enzyme (E2), a carrier protein, through the formation of a thiol ester linkage.  Next, an 
ubiquitin-protein ligase (E3) recruits the substrate targeted for degradation, and ubiquitin 
is transferred to the substrate (see Figure 4).  Finally, the proteosome recognizes the 
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polyubiquitinated substrate, which is degraded into small peptides, and the proteasome 
releases the reusable ubiquitin (Ciechanover, 2001). 
 
Parkin is an E3 Ligase 
The parkin protein functions as an ubiquitin E3 ligase transferring ubiquitin from 
E2 to target proteins.  It ubiquitinates at least 8 substrates that include α-synuclein, Pael-
R, CDC-rel and synphilin-1, which play a role in synapse formation.  It has been 
proposed that mutations in the parkin protein reduces its ability to ubiquitinate these 
substrates, resulting in their accumulation and aggregation that eventually lead to the 
death of nigral neurons in PD patients (Finney et al. 2003). 
Parkin possesses several distinguished domains, each of which has a specific role. 
The two typical RING finger domains and the IBR domain at its c-termiuns interact with 
the E2.  The N-terminal ubiquitin like domain (UBL) of parkin acts as a binding site for 
accessory proteins to regulate the levels of parkin expression and the binding of 
substrates (see Figure 5).  The region between residues 77-313 in the parkin protein can 
be self-ubiquitinated, thus, regulates its own expression levels (Finney et al. 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: The Role of Parkin in the Ubiquitination Pathway (Giasson and 
Lee, 2001).  In this diagram Parkin is represented by the horizontal 
multicolored cylinder. 
 11
 In a normal cell, polyubiquiutinated proteins accumulate in inclusion bodies.  The 
formation of inclusion bodies prevents the accumulation of untagged proteins in the 
cytosol which are toxic to the cell.  Although the mechanism is unknown, once the 
proteins are inside the inclusion body, they are ubiqutinated.  In AR-JP patients, when the 
parkin protein becomes mutated, the ubiquitin system becomes inactive and accumulation 
of proteins that normally would have been ubiquitinated in the Lewy body accumulate in 
the cytosol and cause cell death (see Figure 6) (Ciechanover, 2001). 
 
 
 
 
 
 
 
 
 
      
Figure 6: Formation of Lewy Bodies in PD 
Patients     (Ciechanover 2001). 
 
  
Parkin Mutations 
 
 Mutations in the parkin gene are the most common factor associated with AR-JP.  
Mutations have been found on both alleles in the majority of patients that cause a loss of 
function in the protein.  Such mutations include deletions of exons, duplication of exons, 
insertions and deletions of several basepairs, mutations affecting splicing, and point 
mutations in the C-terminus and RING finger domains (see Figure 7) (Mata et al. 2004). 
 12
  
 
 
 
 
Figure 7: Parkin Protein Domain Structure and 
Known Deletions (Mata et al. 2004). 
. 
 
 
 
 
 
 
 
 
 
 
The most common mutation of the parkin gene is the deletion of one or several 
exons.  Some deletions result in premature termination of translation, and frameshifts 
occur due to deletion of exon 3 and 4, or exon 5 resulting in the formation of truncated 
proteins (see Figure 7).  Mutations affecting splicing commonly affect the splice site 
between exon 5 and 6, and exon 7 and 8.  These mutations result in a truncated, altered 
parkin function (West et al. 2002). 
Point mutations in the parkin DNA sequence result in amino acid substitutions (see 
Figure 3, locations shown above the map).  These mutations are largely located in the C-
terminus of the protein affecting the interaction between E2 and the two RING finger 
domains.  This causes the accumulation of unfolded proteins, which further upregulates 
parkin mRNA.  Overexpression of parkin normally prevents cell death induced by the 
accumulation of unfolded proteins.  Imai et al. have shown that under conditions of 
endoplasmic reticulum (ER) stress caused by the accumulation of unfolded proteins, 
parkin mRNA and protein levels are upregulated preventing dopaminergic cell death.  
This shows the normal protective role of the parkin protein (Imai et al. 2000). 
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Nrdp1 (discovery, size, structure, location, function)   
Neuregulin receptor degradation protein-1 (Nrdp1) was first characterized by 
Abdullah et al (2001).  In order to understand the regulation of tyrosine kinases (TK’s), 
Diamonti et al (2002) performed Yeast Two Hybrid screens to identify and characterize 
the proteins that bind TK’s.  They discovered Nrdp1.  They concluded that one possible 
role of Nrdp1 is in the regulation of overall protein levels in the cell (Diamonti et 
al.2002).  
The Nrdp1 gene is located on chromosome 12 and is 3.1 kilobases long.  This 
gene has a protein coding sequence of 951 bps, encoding a 317 amino acid, 36 kDa 
protein.  The protein contains a RING Finger, two Zinc fingers, and a Coiled coil domain 
(see Figure 8).   
 
 
 
 Figure 8:  Illustration of Nrdp1 Protein Domains (Qiu-Goldberg 2002). 
 
The N-terminus of Nrdp1 contains the RING finger and Zinc finger domains 
which catalyze the ubiquitination of substrates.  The C-terminus contains the substrate 
binding domain which binds the substrates targeted for ubiquitination.  Nrdp1 is 
expressed in a variety of tissues including the brain, heart, and muscle (Qiu and 
Goldberg, 2002). 
Diamonti et al showed that Nrdp1 functions as an E3 ligase, promoting the 
degradation of several proteins including ErbB3, which is an epidermal growth factor 
receptor that functions in the regulation of cell growth and differentiation.  Research done 
 14
by Zhong et al. (2005) has shown that Nrdp1 also interacts with parkin in the brain 
through a yeast two hybrid interaction.  This suggests that Nrdp1 plays a role in 
ubiquitination and subsequent proteosomal degradation of parkin (Zhong et al. 2005).  
Zhong et al. proposed a model for the role of Nrdp1 in the regulation of parkin 
(see Figure 9).  They proposed that increased activity of Nrdp1 is associated with a 
reduction in cellular parkin levels.  This reduction causes an accumulation of parkin 
substrates and thus resulting in cell death.  Decreased activity of Nrdp1 stabilizes parkin 
and protects the cell.  
 
 
Figure 9: Proposed Mechanism of Nrdp1 in Parkin Regulation (Zhong et al. 
2005).  In this model, overexpression of Nrdp1 (yellow) binds parkin leading to 
its degradation in the proteasome, and decreased cellular levels (right side), and 
abnormal aggregation. 
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PROJECT PURPOSE 
 
Mutations in the parkin gene are responsible for Autosomal Recessive Juvenile 
Parkinson’s (AR-JP) disease.  Wild type parkin functions as an E3 ligase in the ubiquitin 
pathway, which transfers ubiquitin from E2 to the target protein.  When a mutation 
occurs in parkin, its function as an E3 ligase is impaired resulting in diminished 
proteasome degradation of its substrates.  An accumulation of these substrates forms 
aggregates and subsequently causes cell death.  Nrdp1 is an ubiquitin E3 ligase that 
interacts with the parkin protein. Nrdp1 significantly reduces parkin’s levels in the cell, 
thus the regulation of interactions between parkin and Nrdp1 may affect the pathogenesis 
of PD.     
The goal of this MQP is to investigate which portion of Nrdp1 binds to parkin.  
Identification of specific motif(s)/domain(s) that is responsible for association between 
parkin and Nrdp1 may provide important clues on how to design therapeutic peptides that 
can reduce Nrdp1 from binding and degrading parkin.  These peptides will potentially 
prevent or slow the accumulation of parkin substrates. Therefore, an improvement on the 
pathogenesis of the disease would be possible. 
To identify the domains in Nrdp1 that interacts with parkin, we used the yeast two 
hybrid assay.  Our data indicates that the region containing domains two and three of 
Nrdp1 specifically interacts with parkin.  More research is needed to precisely pinpoint a 
more defined region of interaction between the two proteins before a specific peptide can 
be designed. 
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METHODS 
 
Primer Design, PCR, and Amplicon Purification   
 The cDNA sequence encoding human full length Nrdp1 was obtained from NCBI 
website accession number NM_194359.  Using the cDNA sequence, PCR primers were 
designed to amplify full-length, N-terminal, and C-terminal regions of Nrdp1 using 
program Primer Designer.  The primers for amplifying the 549 bp N-terminal fragment 
are:  5’-CGGAATTCCGGGGTATGATGTAACCCGT-3’ and  
5’-CCCTCGAGGGGTTGACACTGCGGATTGC-3’.  The primers for amplifying the 
753 bp C-terminal fragment are:  5’-CGGAATTCCGGTACCTCGGATCATGCGG-3’ 
and 5’-CCCTCGAGGGATTTATCTCTTCCACGCC-3’.  The primers for amplifying the 
951 bp full length Nrdp1 cDNA are:  5’-CGGAATTCCGGGGTATGATGTAACCCGT-
3’ and 5’-CCCTCGAGGGATTTATCTCTTCCACGCC-3’.   EcoRI and XhoI restriction 
sites were added to the sense and antisense primers, respectively, to facilitate subsequent 
subcloning.  PCR reactions were carried out under the following conditions: initial 
denaturation at 95ºC for 2 min, and then 35 cycles of denaturation at 95ºC for 1 min, 
annealing at 55ºC for 1 min, extension at 72ºC for 2 min, final extension at 72ºC  for 10 
minutes.    
 PCR products were extracted with phenol:chloroform and then precipitated at 
-20˚C overnight after adding 1/10 volume of 3M of Sodium Acetate (pH 5.2) and 2.5 
volumes of 100% ethanol. Precipitated PCR products were double digested with EcoRI 
and XhoI for 2 hrs at 37ºC.  The digested PCR products were then separated on a 2.0% 
agarose gel run in the presence of ethidium bromide.  The fragments with the correct 
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sizes were purified from 2.0% agarose gels using a gel-extract kit purchased from 
Qiagen. 
Preparation of Competent E. coli for Transformation 
E. coli, strain DH5α, was plated on a LB plate and was grown overnight at 37ºC.  
Two to three colonies were inoculated into 2 mL of LB media and grown overnight at 
37ºC.  This culture was transferred into 200 mL of LB medium and shaken at 37ºC until 
OD600=0.40.  After incubation, the 200 mL culture was spun down at 6000 rpm for 5 
minutes and the supernatant was discarded completely.  The cell pellets were vortexed in 
8 mL of an ice cold, sterile solution of 0.1 M RbCl, 30 mM KAc, 50 mM MnCl2, and 
50% (v/v) glycerol (TF1 buffer).  The cells were put on ice for one hour.  Cells were 
centrifuged at 6000 rpm for 5 minutes, the supernatant was completely removed, and 
cells were resuspended in a 8 mL sterile solution of 10 mM RbCl, 75 mM CaCl2, 15% 
(v/v) glycerol, and 10 mM MOPS (TF2 buffer).  The solution was put on ice for at least 
15 minutes, and 100 µL were aliquoted into cold eppendorf tubes. Tubes were 
immediately frozen on dry ice and were stored at -70ºC. 
 
Generation of Constructs for the Yeast Two Hybrid Assays 
 Full length Nrdp1 cDNA, N-terminal, and C-terminal digested and purfied PCR 
products were ligated into EcoRI/XhoI digested yeast expression plasmid pGADT7 
(Clontech) overnight at 16ºC. Ligation products were transformed into competent DH5α 
E. coli that were prepared by a rubidium chloride protocol (see above) and plated on LB 
plates supplemented with 100 µg/ml ampicillin.   Full-length Parkin cDNA in pGBKT7 
in E. coli was kindly provided by J. Zhou. 
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Screening of Positive Subclones 
 Individual ampicillin-resistant E. coli colonies were inoculated into 2 mL of LB 
with 50 µg/ml of ampicillin and grown overnight at 37ºC.  Plasmid DNAs were purified 
from cultures using the Qiagen miniprep procedure.  The purified plasmids were digested 
with EcoRI and XhoI, and separated on 1% agarose gels.  The plasmid DNAs that 
contained inserts with the correct sizes were sequenced.  
 
The Yeast Two Hybrid Assay  
The Matchmaker Yeast Two-Hybrid System was purchased from CLONTECH.  
The Y190 lacZ/HIS3 yeast reporter strain was streaked on YPD plates and incubated at 
30ºC for 4 days. 3-4 colonies of Y190 were transferred into 1 mL of YPD media and 
vortexed to disperse any clumps.  The 1 mL was transferred into 70 mL of YPD media 
and incubated at 30ºC for 16-18 hours at 250 rpm to achieve stationary phase 
(OD600>1.5).  Approximatly 50 mL of this overnight culture was transferred into 150 mL 
of fresh YPD media to reach an OD600=0.2-0.3 and was incubated at 30ºC at 230 rpm 
until OD600=0.40-0.60.  Cells were harvested by centrifugation at 1000 x g at room 
temperature for 5 minutes.  The supernatant was discarded, and cells were resuspended in 
25 mL of sterile H2O.  Resuspened cells were centrifuged again at 1000 x g at room 
temperature for 5 minutes.  The supernatant was decanted and cells were resuspended in 
1.5 mL of freshly prepared, sterile 1X TE/LiAc.   
To test the Yeast Two-Hybrid System, control plasmids, pCL1, pGADT7-T, 
pGBKT7-53, pGBKT7-Lam, provided by Clontech were used.  Three mixtures were 
performed:  pCL1 and pGBKT7-53, pGADT7-T and pGBKT7-53, and pGADT7-T and 
pGBKT7-Lam.  To test the interaction between parkin and Nrdp1, 0.1 µg of purified bait 
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plasmid (pGBKT7) containing the Gal4 DNA binding domain, 0.1 µg of prey plasmid 
(pGADT7) containing the Gal4 activation domain, and 0.1 mg of herring testes carrier 
DNA were mixed with 100 µL of the yeast cell suspension.  Eight mixtures were 
performed:  pGBKT7-parkin cDNA and pGADT7-Nrdp1 N-terminus, pGBKT7-parkin 
cDNA and pGADT7-Nrdp1 C-terminus, pGBKT7-parkin cDNA and pGADT7-full 
length Nrdp1, pGBKT7-parkin cDNA and pGADT7 (no insert), pGBKT7 (no insert) and 
pGADT7 (no insert),  pGBKT7  (no insert) and pGADT7-Nrdp1 N-terminus, pGBKT7 
(no insert) and  pGADT7-Nrdp1 C-terminus, and pGBKT7 (no insert) and pGADT7-full 
length Nrdp1.   
600 µL of 40% PEG/LiAc solution was added to each tube, mixed and incubated 
at 30ºC for 30 minutes at 200 rpm.  After incubation, 70 µL of DMSO was added to each 
tube and gently inverted to mix.  Tubes were heat shocked for 15 minutes in a 42ºC water 
bath and then chilled on ice for 2 minutes.  Cells were pelleted by centrifugation for 5 
seconds at 14,000 rpm.  Supernatant was removed from each tube, and transformed cells 
were resuspended in 0.5 mL of 1X TE buffer.  Transformed cells were plated on SD  
–Leu/-Trp media and grown for 4 days for initial selection.   
For the colony lift filter β–galactosidase assay, transformed colonies were 
replated on a new SD –Leu/-Trp plate.  A Whatman #3 filter was presoaked in Z-
buffer/X-gal solution.  A dry Whatman #3 filter was placed over one set of plates to be 
assayed.  The filter was transferred into a pool of liquid nitrogen for 10 seconds.  This 
filter was then placed on the presoaked filter and incubated at 30ºC for 30 minutes to 2 
hours for the appearance of blue colonies.  Interaction between bait and prey proteins (i.e. 
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parkin and Nrdp1) restores Gal4 function, resulting in expression of the β-galactosidase 
reporter gene, and the apparance of blue colonies. 
For the α-galactosidase assay, transformed colonies were plated on an SD –Leu/-
Trp plate with 100 µL of α-galactosidase.  Plates were incubated at 30ºC for 4 days.  
Plates were observed for a blue/white color change.  Interaction between bait and prey 
proteins (i.e. parkin and Nrdp1) restores Gal4 function, resulting in expression of the α-
galactosidase reporter gene, and the apparance of blue colonies.   
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RESULTS 
 
The aim of the project is to identify which region of Nrdp1 binds to parkin.  If we 
can identify this sequence of Nrdp1, it is possible to produce a therapeutic peptide to 
reduce Nrdp1 from binding and degrading parkin.  This potentially will prevent or slow 
the accumulation of substrates and cause an improvement on the pathogenesis of the 
disease.  To identify the location of the interaction between parkin and Nrdp1, we used 
the yeast two hybrid screen. 
 
Successful Ligation of Nrdp1 PCR Products into Plasmid pGADT7 
Three kinds of Nrdp1 inserts (full-length, N-terminus, and C-terminus) were 
amplified from an Nrdp1-containing plasmid by PCR using primers containing EcoRI 
and XhoI sites at their termini. The amplicons were double digested to produce EcoRI 
and XhoI termini, and ligated into EcoRI/XhoI cut yeast expression plasmid pGADT7.  
   
Selection of Transformed E. coli Positives 
 In order to confirm the effective subcloning of pGADT7 recombinants in E. coli, 
we transformed E. coli with the three ligated plasmids and plated them on 100 µg/ml 
ampcillin plates.  Individual colonies were grown, and plasmids were purified from 
cultures using the Qiagen miniprep procedure.  Figure 10a shows digested pGADT7 
containing full-length and the N-terminus of Nrdp1.  Verification of the cloning of the C-
terminus is shown in figure 10b.  Since the band with the correct insert was released from 
the plasmid, this confirms an accurate subcloning of the three constructs. 
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Figure 10a:  TOP portion of gel:  Dropout of full length Nrdp1 from 
digested pGADT7 of subcloned E. coli colonies.  BOTTOM:  Dropout 
of the N-terminus of Nrdp1 from digested pGADT7 of subcloned E. 
coli colonies. 
 
 
 
 
 
 
Figure 10b:  Drop out analysis of the C-terminus of Nrdp1 
from digested pGADT7 of cloned E. coli colonies. 
 
 
 
 
 
 
 
Validation of Constructs 
To confirm the successful construction of the three yeast expression plasmids, we 
double-digested the recombinant pGADT7 plasmids with restriction enzymes EcoRI and 
XhoI for dropout analysis.  The original PCR-amplified Nrdp1 fragments, along side the 
double digested pGADT7, are shown in Figure 11.  The N-terminus fragment of Nrdp1, 
549 bp in length, contains the ring finger domain and the two zinc finger domains, 
whereas the C-terminus fragment of Nrdp1, 753 bps in length, contains the two zinc 
finger domains and the coiled coil domain (see previous Figure 8).  Since the PCR 
fragment corresponded to the dropout in each instance, we were able to conclude that the 
correct fragment was successfully ligated into the each expression vector. For further 
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clarification, minipreps of plasmids containing the three Nrdp1 inserts were prepared and 
sent for sequencing.  The data, provided in Appendix A, proves that the desired insert 
was properly ligated into each plasmid. 
 
Figure 11.  Agarose gel demonstrating proper ligation of Nrdp1 PCR fragments into the pGADT7 plasmid.  
pGADT7 recombinants were double digested with EcoRI and XhoI restriction enzymes.  Equal masses of 
PCR fragment and digested pGADT7 were run on a 2% agarose gel and stained with ethidium bromide. 
 
 
Yeast Two Hybrid System  
The principle of the yeast two hybrid system is to utilize a growth selection to 
determine protein-protein interactions.  Eukaryotic DNA transcription factors are made of 
both a DNA binding domain (DNA-BD) and activation domain (AD).  The yeast GAL4 
transcriptional activator contains both of these domains. The DNA-BD recognizes and 
binds to the upstream activating sequence of the gene, while the AD interacts with the 
DNA-BD and other transcription factors to initiate transcription.  These two domains are 
required to activate transcription of the gene (see Figure 12). 
In the yeast two hybrid system, two different vectors are used to generate separate 
fusions of the GAL4 domains to genes encoding proteins that potentially interact.  
pGADT7 and pGBKT7 encode for the AD and DNA BD, respectively.  The two fusion 
proteins are co-expressed in yeast.  If the two non-GAL4 portions of the fusion proteins 
951 bp 
549 bp 
753 bp 
Full Length 
PCR/Dropout 
N-terminus 
PCR/Dropout 
C-terminus 
PCR/Dropout
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interact, the DNA-BD and AD will combine and the GAL4 transcriptional activator will 
be functional to transcribe the reporter genes (see Figure 12).  
 
  Figure 12:  Schematic of the Yeast Two Hybrid System (Clontech). 
 
The two plasmids, pGADT7 and pGBKT7, are cotransformed into the yeast strain 
Y190.  Since pGADT7 and pGBKT7 contain selection markers for leucine and 
tryptophan, respectively, transformants are plated on synthetic dropout (SD) media 
lacking the amino acids leucine and tryptophan to select for colonies that contain both 
plasmids.  The GAL4 responsive genes consist of MEL1, lacZ, ADE2, and HIS3 reporter 
genes.  Expression of the MEL1 reporter gene is positive for α –galactosidase activity.  
Expression of the lacZ reporter gene is positive for β-galactosidase activity, whereas 
expression of the HIS3 and ADE2 reporter genes does not require addition of histidine or 
adenine in the media to grow.  
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Utilization of the Yeast Two Hybrid System 
To demonstrate a mastery of the yeast two hybrid assay, the controls provided by 
Clontech were tested.  Three control mixtures, pCL1 and pGBKT7-53, pGADT7-T and 
pGBKT7-53, and pGADT7-T and pGBKT7-Lam, were co-transformed into yeast.  pCL1 
provides a positive control for α and β-galactosidase assays because it encodes the full-
length GAL4 protein.  pGBKT7-53 and pGADT7-T also provide positive control since 
they encode fusion proteins between the GAL4 DNA-BD and AD, and murine p53 and 
SV40 large T-antigen, respectively.  Murine p53 and SV40 T-antigen are known to 
interact strongly.  pGBKT7-Lam provides a negative control since it encodes a fusion of 
DNA-BD with human lamin C, which does not interact with either murine p53 or SV40 
T-antigen. 
The transformed yeast were plated on a SD –Leu/-Trp plate to select for 
transformants containing both plasmids.  Positive transformants were transferred to a 
fresh SD –Leu/-Trp plate containing an X-gal solution.  As seen in Figure 13, 
cotransformation of the controls yielded both positive and negative colonies for a α –
galactosidase assay.  The blue colonies represent cleavage of the X-gal substrate leaving 
a water insoluble blue product. 
  
Figure 13:  Control Plate for Testing the Yeast Two Hybrid System.  
The arrows denote the formation of blue color for positive colonies. 
 26
Nrdp1/Parkin Protein-Protein Interactions 
To investigate the binding regions between parkin and Nrdp1, we cotransformed 
the three constructs, full length, N-terminus, and C-terminus of Nrdp1, into yeast strain 
Y190.  To select for transformants containing both plasmids, yeast were plated on a SD –
Leu/-Trp plate.  Positive double-transformants were then transferred onto a SD -Leu/-
Trp/-Ade/-His plate to select for a positive interaction between parkin and Nrdp1.  As 
seen on the left plate of Figure 14, yeast colonies grew in all three sections (containing: 
parkin and full length Nrdp1, parkin and N-terminus, and parkin and C-terminus) for this 
selective medium.  From this we can infer that interacting region between parkin and 
Nrdp1 is most likely located in the overlapping region of the two N-terminal and C-
terminal fragments containing zinc finger domains two and three (see Figure 8 in 
Background).   
Illustrated in the right plate of Figure 14 is a colony lift filter β-galactosidase 
assay.  Although yeast colonies grew on the SD -Leu/-Trp/-Ade/-His plate indicating an 
interaction between the two proteins, no colonies turned blue on the β-galactosidase 
assay.  This indicates a possible weak interaction between the two proteins. 
 
Figure 14:  Protein-protein interaction between parkin and full-length, N-terminus, and C-terminus of 
Nrdp1.  LEFT:  Growth of double plasmid-transformed yeast colonies on a SD -Leu/-Trp/-Ade/-His plate 
showing growth for all three Nrdp1 constructs tested.  This signifies an interaction between parkin and 
domains two and three of Nrdp1.  RIGHT:  β-galactosidase assay of yeast colonies on a SD -Leu/-Trp/-
Ade/-His plate, showing weak blue staining.  This implies a weak interaction between the two proteins. 
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DISCUSSION 
 
Autosomal Recessive Juvenile Parkinson's disease (AR-JP) is caused by a 
mutation in the parkin gene.  The parkin protein functions as an E3 ligase in the ubiquitin 
pathway, and loss of parkin function results in cell death. Nrdp1 is a protein that interacts 
with parkin reducing its stability, activity, and its levels in the cell.  Regulating the 
interactions between parkin and Nrdp1 may thus affect the pathogenesis of AR-JP. 
In this project, yeast expression plasmid constructs were successfully generated in 
pGADT7 containing the full-length, N-terminus, and C-terminus of Nrdp1.  The plasmids 
were transformed into yeast, and tested using the yeast two hybrid system for interactions 
with parkin.  The data demonstrated the interaction between parkin and Nrdp1, and this 
interaction was effectively narrowed to the region of Nrdp1 containing zinc finger 
domains two and three (see Fig 8 in Background) since only those domains are common 
to all three fragments tested.  Subsequent to the onset of this project, Zhong et. al. (2005) 
illustrated through westerns, co-immunoprecipitation, and the yeast two hybrid system an 
interaction between parkin and Nrdp1.  Our β-galactosidase assay did not provide blue 
colonies, so it is reasonable to presume that the interaction between the two proteins is 
weak, but colonies were observed on plate screenings with appropriate media selections 
for the interaction.  
The identified region of Nrdp1 that interacts with parkin contains two zinc 
fingers.  Little is known on how zinc finger domains regulate protein-protein interactions, 
but some evidence exists that such domains facilitate the interaction with zinc finger 
domains in other proteins.  This finding has potential for research to examine a further 
understanding of the mechanism involved.  Future experiments would include narrowing 
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down the interacting region further to possibly a few amino acids.  This would include 
testing whether domain two or three, or domain two and three are necessary for the 
protein-protein interaction between parkin and Nrdp1.  This would lead researchers closer 
to producing a therapeutic peptide to interfere with Nrdp1 from binding and degrading 
parkin, and cause an improvement on the pathogenesis of the disease.  Efforts have been 
made to begin this process.   
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APPENDIX A 
A.1 Sequencing data for full length Nrdp1 construct 
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A.2 Sequencing data for N-terminus Nrdp1 construct 
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A.3 Sequencing data for C-terminus Nrdp1 construct 
 
 
